Journal of Osteoporosis最新文献_第7页

The Effects of Noncompliance to Prolia (Denosumab) on the Changes in Bone Mineral Density: A Retrospective Review 不遵医嘱服用Prolia (Denosumab)对骨密度变化的影响:回顾性回顾

IF 1.9

Journal of Osteoporosis Pub Date : 2016-01-04 DOI: 10.1155/2016/7903128

M. Wong-Pack, A. Kalani, J. Hordyk, G. Ioannidis, R. Bensen, W. Bensen, A. Papaioannou, J. Adachi, A. Lau

{"title":"The Effects of Noncompliance to Prolia (Denosumab) on the Changes in Bone Mineral Density: A Retrospective Review","authors":"M. Wong-Pack, A. Kalani, J. Hordyk, G. Ioannidis, R. Bensen, W. Bensen, A. Papaioannou, J. Adachi, A. Lau","doi":"10.1155/2016/7903128","DOIUrl":"https://doi.org/10.1155/2016/7903128","url":null,"abstract":"Although denosumab (Prolia) has been shown to be a safe and efficacious therapy for osteoporotic patients in numerous clinical trials, few studies have determined its effectiveness in real world clinical practice. A retrospective review of patients prescribed Prolia assessing the impact that noncompliance from the regular dosing regimen of six months for denosumab has on bone mineral density (BMD) was performed. 924 patient records were reviewed between August 2012 and September 2013 with 436 patients meeting the eligibility criteria. Patients were divided into three groups: subsequent injection of denosumab (1) less than five months, (2) between five and seven months, and (3) more than seven months after their initial subcutaneous injection. A multivariable regression analysis was conducted comparing the differences among the three prespecified groups in BMD change (g/cm2) after one year of denosumab therapy at both the lumbar spine (LS) and femoral neck (FN). The differences in LS and FN BMD have shown that the relationship between the timing of drug administration in these three groups and change in BMD over 1 year was not clinically or statistically significant (p > 0.05). A follow-up study with a larger sample size and longer follow-up duration is required to further characterize this relationship.","PeriodicalId":45384,"journal":{"name":"Journal of Osteoporosis","volume":"77 1","pages":""},"PeriodicalIF":1.9,"publicationDate":"2016-01-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"87302113","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 1

Effect of Denosumab on Bone Mineral Density and Markers of Bone Turnover among Postmenopausal Women with Osteoporosis. 地诺单抗对绝经后骨质疏松妇女骨密度和骨转换标志物的影响。

IF 1.9

Journal of Osteoporosis Pub Date : 2016-01-01 Epub Date: 2016-08-08 DOI: 10.1155/2016/8738959

A Sánchez, L R Brun, H Salerni, P R Costanzo, D González, A Bagur, B Oliveri, M B Zanchetta, V Farías, L Maffei, V Premrou, J L Mansur, M S Larroudé, M A Sarli, P Rey, M R Ulla, M M Pavlove, S Karlsbrum, M L Brance

{"title":"Effect of Denosumab on Bone Mineral Density and Markers of Bone Turnover among Postmenopausal Women with Osteoporosis.","authors":"A Sánchez, L R Brun, H Salerni, P R Costanzo, D González, A Bagur, B Oliveri, M B Zanchetta, V Farías, L Maffei, V Premrou, J L Mansur, M S Larroudé, M A Sarli, P Rey, M R Ulla, M M Pavlove, S Karlsbrum, M L Brance","doi":"10.1155/2016/8738959","DOIUrl":"https://doi.org/10.1155/2016/8738959","url":null,"abstract":"The aim of this study was to evaluate the effect of denosumab (Dmab) on bone mineral density (BMD) and bone turnover markers after 1 year of treatment. Additionally, the effect of Dmab in bisphosphonate-naïve patients (BP-naïve) compared to patients previously treated with bisphosphonates (BP-prior) was analyzed. This retrospective study included 425 postmenopausal women treated with Dmab for 1 year in clinical practice conditions in specialized centers from Argentina. Participants were also divided according to previous bisphosphonate treatment into BP-naïve and BP-prior. A control group of patients treated with BP not switched to Dmab matched by sex, age, and body mass index was used. Data are expressed as mean ± SEM. After 1 year of treatment with Dmab the bone formation markers total alkaline phosphatase and osteocalcin were significantly decreased (23.36% and 43.97%, resp.), as was the bone resorption marker s-CTX (69.61%). Significant increases in BMD were observed at the lumbar spine, femoral neck, and total hip without differences between BP-naïve and BP-prior. A better BMD response was found in BP-prior group compared with BP treated patients not switched to Dmab. Conclusion. Dmab treatment increased BMD and decreased bone turnover markers in the whole group, with similar response in BP-naïve and BP-prior patients. A better BMD response in BP-prior patients versus BP treated patients not switched to Dmab was observed. ","PeriodicalId":45384,"journal":{"name":"Journal of Osteoporosis","volume":"2016 ","pages":"8738959"},"PeriodicalIF":1.9,"publicationDate":"2016-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1155/2016/8738959","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"34405114","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 14

Bone Mineral Density in Postmenopausal Women Heterozygous for the C282Y HFE Mutation. 绝经后妇女C282Y HFE突变的杂合骨密度。

IF 1.9

Journal of Osteoporosis Pub Date : 2016-01-01 Epub Date: 2016-03-31 DOI: 10.1155/2016/5638273

Jenny E Gunton, Frances Gates, Greg R Fulcher, Phillip B Clifton-Bligh

{"title":"Bone Mineral Density in Postmenopausal Women Heterozygous for the C282Y HFE Mutation.","authors":"Jenny E Gunton, Frances Gates, Greg R Fulcher, Phillip B Clifton-Bligh","doi":"10.1155/2016/5638273","DOIUrl":"https://doi.org/10.1155/2016/5638273","url":null,"abstract":"Mutations in the HFE gene may be associated with increased tissue iron stores reflected in an elevated serum ferritin. With homozygous mutation C282Y, the increase in serum ferritin may be associated with tissue damage in the liver, pancreas, and pituitary and with a reduced bone mineral density. With heterozygous mutation C282Y, the degree of iron retention is less but information relating to how a heterozygous C282Y mutation might impact bone mineral density is uncertain. The present study was undertaken to study the relationships between bone mineral density measured by dual energy X-ray absorptiometry and the serum ferritin and serum iron in postmenopausal women heterozygous for the C282Y mutation. The spinal bone mineral density, L2-4, was significantly less than age matched community controls (P = 0.016). There was no significant change in the femoral neck bone mineral density compared to age matched community controls. The correlation between the spinal bone mineral density, L2-4, the femoral neck bone mineral density, and the serum ferritin was not significant. The serum iron correlated significantly inversely with the femoral neck bone mineral density (P = 0.048). The heterozygous C282Y mutation may be associated with impairment of bone cell function in postmenopausal women when only small increases in the serum iron or serum ferritin have occurred. ","PeriodicalId":45384,"journal":{"name":"Journal of Osteoporosis","volume":"2016 ","pages":"5638273"},"PeriodicalIF":1.9,"publicationDate":"2016-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1155/2016/5638273","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"34439050","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 2

Sclerostin Antibody Therapy for the Treatment of Osteoporosis: Clinical Prospects and Challenges. 治疗骨质疏松症的硬骨蛋白抗体疗法：临床前景与挑战。

IF 1.9

Journal of Osteoporosis Pub Date : 2016-01-01 Epub Date: 2016-05-26 DOI: 10.1155/2016/6217286

Claire MacNabb, D Patton, J S Hayes

{"title":"Sclerostin Antibody Therapy for the Treatment of Osteoporosis: Clinical Prospects and Challenges.","authors":"Claire MacNabb, D Patton, J S Hayes","doi":"10.1155/2016/6217286","DOIUrl":"10.1155/2016/6217286","url":null,"abstract":"It is estimated that over 200 million adults worldwide have osteoporosis, a disease that has increasing socioeconomic impact reflected by unsustainable costs associated with disability, fracture management, hospital stays, and treatment. Existing therapeutic treatments for osteoporosis are associated with a variety of issues relating to use, clinical predictability, and health risks. Consequently, additional novel therapeutic targets are increasingly sought. A promising therapeutic candidate is sclerostin, a Wnt pathway antagonist and, as such, a negative regulator of bone formation. Sclerostin antibody treatment has demonstrated efficacy and superiority compared to other anabolic treatments for increasing bone formation in both preclinical and clinical settings. Accordingly, it has been suggested that sclerostin antibody treatment is set to achieve market approval by 2017 and aggressively compete as the gold standard for osteoporotic treatment by 2021. In anticipation of phase III trial results which may potentially signify a significant step in achieving market approval here, we review the preclinical and clinical emergence of sclerostin antibody therapies for both osteoporosis and alternative applications. Potential clinical challenges are also explored as well as ongoing developments that may impact on the eventual clinical application of sclerostin antibodies as an effective treatment of osteoporosis. ","PeriodicalId":45384,"journal":{"name":"Journal of Osteoporosis","volume":"2016 ","pages":"6217286"},"PeriodicalIF":1.9,"publicationDate":"2016-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4899597/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"34650746","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Association of Trabecular Bone Score with Inflammation and Adiposity in Patients with Psoriasis: Effect of Adalimumab Therapy. 银屑病患者骨小梁评分与炎症和肥胖的关系:阿达木单抗治疗的效果。

IF 1.9

Journal of Osteoporosis Pub Date : 2016-01-01 Epub Date: 2016-05-12 DOI: 10.1155/2016/5747852

José L Hernández, Raquel López-Mejías, Ricardo Blanco, Trinitario Pina, Sheila Ruiz, Isabel Sierra, Begoña Ubilla, Verónica Mijares, Marcos A González-López, Susana Armesto, Alfonso Corrales, Enar Pons, Patricia Fuentevilla, Carmen González-Vela, Miguel Á González-Gay

{"title":"Association of Trabecular Bone Score with Inflammation and Adiposity in Patients with Psoriasis: Effect of Adalimumab Therapy.","authors":"José L Hernández, Raquel López-Mejías, Ricardo Blanco, Trinitario Pina, Sheila Ruiz, Isabel Sierra, Begoña Ubilla, Verónica Mijares, Marcos A González-López, Susana Armesto, Alfonso Corrales, Enar Pons, Patricia Fuentevilla, Carmen González-Vela, Miguel Á González-Gay","doi":"10.1155/2016/5747852","DOIUrl":"https://doi.org/10.1155/2016/5747852","url":null,"abstract":"Studies on trabecular bone score (TBS) in psoriasis are lacking. We aim to assess the association between TBS and inflammation, metabolic syndrome features, and serum adipokines in 29 nondiabetic patients with psoriasis without arthritis, before and after 6-month adalimumab therapy. For that purpose, adjusted partial correlations and stepwise multivariable linear regression analysis were performed. No correlation was found between TBS and disease severity. TBS was negatively associated with weight, BMI, waist perimeter, fat percentage, and systolic and diastolic blood pressure before and after adalimumab. After 6 months of therapy, a negative correlation between TBS and insulin resistance (p = 0.02) and leptin (p = 0.01) and a positive correlation with adiponectin were found (p = 0.01). The best set of predictors for TBS values at baseline were female sex (p = 0.015), age (p = 0.05), and BMI (p = 0.001). The best set of predictors for TBS following 6 months of biologic therapy were age (p = 0.001), BMI (p < 0.0001), and serum adiponectin levels (p = 0.027). In conclusion, in nondiabetic patients with moderate-to-severe psoriasis, TBS correlates with metabolic syndrome features and inflammation. This association is still present after 6 months of adalimumab therapy. Moreover, serum adiponectin levels seem to be an independent variable related to TBS values, after adalimumab therapy. ","PeriodicalId":45384,"journal":{"name":"Journal of Osteoporosis","volume":"2016 ","pages":"5747852"},"PeriodicalIF":1.9,"publicationDate":"2016-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1155/2016/5747852","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"34473662","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 13

Cross-Calibration of GE Healthcare Lunar Prodigy and iDXA Dual-Energy X-Ray Densitometers for Bone Mineral Measurements. 用于骨矿物质测量的GE医疗保健Lunar Prodigy和iDXA双能x射线密度仪的交叉校准。

IF 1.9

Journal of Osteoporosis Pub Date : 2016-01-01 Epub Date: 2016-04-27 DOI: 10.1155/2016/1424582

J Saarelainen, M Hakulinen, T Rikkonen, H Kröger, M Tuppurainen, H Koivumaa-Honkanen, R Honkanen, M Hujo, J S Jurvelin

{"title":"Cross-Calibration of GE Healthcare Lunar Prodigy and iDXA Dual-Energy X-Ray Densitometers for Bone Mineral Measurements.","authors":"J Saarelainen, M Hakulinen, T Rikkonen, H Kröger, M Tuppurainen, H Koivumaa-Honkanen, R Honkanen, M Hujo, J S Jurvelin","doi":"10.1155/2016/1424582","DOIUrl":"https://doi.org/10.1155/2016/1424582","url":null,"abstract":"In long-term prospective studies, dual-energy X-ray absorptiometry (DXA) devices need to be inevitably changed. It is essential to assess whether systematic differences will exist between measurements with the new and old device. A group of female volunteers (21-72 years) underwent anteroposterior lumbar spine L2-L4 (n = 72), proximal femur (n = 72), and total body (n = 62) measurements with the Prodigy and the iDXA scanners at the same visit. The bone mineral density (BMD) measurements with these two scanners showed a high linear association at all tested sites (r = 0.962-0.995; p < 0.0001). The average iDXA BMD values were 1.5%, 0.5%, and 0.9% higher than those of Prodigy for lumbar spine (L2-L4) (p < 0.0001), femoral neck (p = 0.048), and total hip (p < 0.0001), respectively. Total body BMD values measured with the iDXA were -1.3% lower (p < 0.0001) than those measured with the Prodigy. For total body, lumbar spine, and femoral neck, the BMD differences as measured with these two devices were independent of subject height and weight. Linear correction equations were developed to ensure comparability of BMD measurements obtained with both DXA scanners. Importantly, use of equations from previous studies would have increased the discrepancy between these particular DXA scanners, especially at hip and at spine. ","PeriodicalId":45384,"journal":{"name":"Journal of Osteoporosis","volume":"2016 ","pages":"1424582"},"PeriodicalIF":1.9,"publicationDate":"2016-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1155/2016/1424582","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"34425167","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 18

Denosumab for Elderly Men with Osteoporosis: A Cost-Effectiveness Analysis from the US Payer Perspective Denosumab用于老年男性骨质疏松症:从美国付款人的角度进行成本-效果分析

IF 1.9

Journal of Osteoporosis Pub Date : 2015-12-09 DOI: 10.1155/2015/627631

S. Silverman, I. Agodoa, M. Kruse, A. Parthan, E. Orwoll

{"title":"Denosumab for Elderly Men with Osteoporosis: A Cost-Effectiveness Analysis from the US Payer Perspective","authors":"S. Silverman, I. Agodoa, M. Kruse, A. Parthan, E. Orwoll","doi":"10.1155/2015/627631","DOIUrl":"https://doi.org/10.1155/2015/627631","url":null,"abstract":"Purpose. To evaluate the cost-effectiveness of denosumab versus other osteoporotic treatments in older men with osteoporosis from a US payer perspective. Methods. A lifetime cohort Markov model previously developed for postmenopausal osteoporosis (PMO) was used. Men in the model were 78 years old, with a BMD T-score of −2.12 and a vertebral fracture prevalence of 23%. During each 6-month Markov cycle, patients could have experienced a hip, vertebral or nonhip, nonvertebral (NHNV) osteoporotic fracture, remained in a nonfracture state, remained in a postfracture state, or died. Background fracture risks, mortality rates, persistence rates, health utilities, and medical and drug costs were derived from published sources. Previous PMO studies were used for drug efficacy in reducing fracture risk. Lifetime expected costs and quality-adjusted life-years (QALYs) were estimated for denosumab, generic alendronate, risedronate, ibandronate, teriparatide, and zoledronate. Results. Denosumab had an incremental cost-effectiveness ratio (ICER) of $16,888 compared to generic alendronate and dominated all other treatments. Results were most sensitive to changes in costs of denosumab and the relative risk of hip fracture. Conclusion. Despite a higher annual treatment cost compared to other medications, denosumab is cost-effective compared to other osteoporotic treatments in older osteoporotic US men.","PeriodicalId":45384,"journal":{"name":"Journal of Osteoporosis","volume":"1 1","pages":""},"PeriodicalIF":1.9,"publicationDate":"2015-12-09","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"89659332","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 23

Association of bone loss with the upregulation of survival-related genes and concomitant downregulation of Mammalian target of rapamycin and osteoblast differentiation-related genes in the peripheral blood of late postmenopausal osteoporotic women. 绝经后晚期骨质疏松症妇女外周血中存活相关基因的上调和哺乳动物雷帕霉素靶蛋白及成骨细胞分化相关基因的下调与骨质流失的关系

IF 1.9

Journal of Osteoporosis Pub Date : 2015-01-01 Epub Date: 2015-02-10 DOI: 10.1155/2015/802694

Elena V Tchetina, Karina A Maslova, Mikhail Y Krylov, Valery A Myakotkin

{"title":"Association of bone loss with the upregulation of survival-related genes and concomitant downregulation of Mammalian target of rapamycin and osteoblast differentiation-related genes in the peripheral blood of late postmenopausal osteoporotic women.","authors":"Elena V Tchetina, Karina A Maslova, Mikhail Y Krylov, Valery A Myakotkin","doi":"10.1155/2015/802694","DOIUrl":"https://doi.org/10.1155/2015/802694","url":null,"abstract":"We aimed to identify bone related markers in the peripheral blood of osteoporotic (OP) patients that pointed toward molecular mechanisms underlying late postmenopausal bone loss. Whole blood from 22 late postmenopausal OP patients and 26 healthy subjects was examined. Bone mineral density (BMD) was measured by DXA. Protein levels of p70-S6K, p21, MMP-9, TGFβ1, and caspase-3 were quantified by ELISA. Gene expression was measured using real-time RT-PCR. OP registered by low BMD indices in late postmenopausal patients was associated with a significant upregulation of autophagy protein ULK1, cyclin-dependent kinase inhibitor p21, and metalloproteinase MMP-9 gene expression in the blood compared to the healthy controls and in a significant downregulation of mTOR (mammalian target of rapamycin), RUNX2, and ALPL gene expression, while expression of cathepsin K, caspase-3, transforming growth factor (TGF) β1, interleukin- (IL-) 1β, and tumor necrosis factor α (TNFα) was not significantly affected. We also observed a positive correlation between TGFβ1 and RUNX2 expression and BMD at femoral sites in these patients. Therefore, bone loss in late postmenopausal OP patients is associated with a significant upregulation of survival-related genes (ULK1 and p21) and MMP-9, as well as the downregulation of mTOR and osteoblast differentiation-related genes (RUNX2 and ALPL) in the peripheral blood compared to the healthy controls. ","PeriodicalId":45384,"journal":{"name":"Journal of Osteoporosis","volume":"2015 ","pages":"802694"},"PeriodicalIF":1.9,"publicationDate":"2015-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1155/2015/802694","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"33120872","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 7

Whole-Body Electromyostimulation to Fight Osteopenia in Elderly Females: The Randomized Controlled Training and Electrostimulation Trial (TEST-III). 全身肌电刺激对抗老年女性骨质减少:随机对照训练和电刺激试验(TEST-III)。

IF 1.9

Journal of Osteoporosis Pub Date : 2015-01-01 Epub Date: 2015-02-15 DOI: 10.1155/2015/643520

Simon von Stengel, Michael Bebenek, Klaus Engelke, Wolfgang Kemmler

{"title":"Whole-Body Electromyostimulation to Fight Osteopenia in Elderly Females: The Randomized Controlled Training and Electrostimulation Trial (TEST-III).","authors":"Simon von Stengel, Michael Bebenek, Klaus Engelke, Wolfgang Kemmler","doi":"10.1155/2015/643520","DOIUrl":"https://doi.org/10.1155/2015/643520","url":null,"abstract":"Whole-body electromyostimulation (WB-EMS) has been shown to be effective in increasing muscle strength and mass in elderly women. Because of the interaction of muscles and bones, these adaptions might be related to changes in bone parameters. 76 community-living osteopenic women 70 years and older were randomly assigned to either a WB-EMS group (n = 38) or a control group (CG: n = 38). The WB-EMS group performed 3 sessions every 14 days for one year while the CG performed gymnastics containing identical exercises without EMS. Primary study endpoints were bone mineral density (BMD) at lumbar spine (LS) and total hip (thip) as assessed by DXA. After 54 weeks of intervention, borderline nonsignificant intergroup differences were determined for LS-BMD (WB-EMS: 0.6 ± 2.5% versus CG -0.7 ± 2.5%, P = .051) but not for thip-BMD (WB-EMS: -1.1 ± 1.9% versus CG: -0.8 ± 2.3%, P = .771). With respect to secondary endpoints, there was a gain in lean body mass (LBM) of 1.5% (P = .006) and an increase in grip strength of 8.4% (P = .000) in the WB-EMS group compared to CG. WB-EMS effects on bone are less pronounced than previously reported effects on muscle mass. However, for subjects unable or unwilling to perform intense exercise programs, WB-EMS may be an option for maintaining BMD at the LS. ","PeriodicalId":45384,"journal":{"name":"Journal of Osteoporosis","volume":"2015 ","pages":"643520"},"PeriodicalIF":1.9,"publicationDate":"2015-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1155/2015/643520","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"33139847","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 50

Type 1 diabetes and osteoporosis: from molecular pathways to bone phenotype. 1型糖尿病和骨质疏松:从分子途径到骨骼表型。

IF 1.9

Journal of Osteoporosis Pub Date : 2015-01-01 Epub Date: 2015-03-22 DOI: 10.1155/2015/174186

Tayyab S Khan, Lisa-Ann Fraser

{"title":"Type 1 diabetes and osteoporosis: from molecular pathways to bone phenotype.","authors":"Tayyab S Khan, Lisa-Ann Fraser","doi":"10.1155/2015/174186","DOIUrl":"https://doi.org/10.1155/2015/174186","url":null,"abstract":"The link between type 1 diabetes mellitus (DM1) and osteoporosis, identified decades ago, has gained attention in recent years. While a number of cellular mechanisms have been postulated to mediate this association, it is now established that defects in osteoblast differentiation and activity are the main culprits underlying bone fragility in DM1. Other contributing factors include an accumulation of advanced glycation end products (AGEs) and the development of diabetes complications (such as neuropathy and hypoglycemia), which cause further decline in bone mineral density (BMD), worsening geometric properties within bone, and increased fall risk. As a result, patients with DM1 have a 6.9-fold increased incidence of hip fracture compared to controls. Despite this increased fracture risk, bone fragility remains an underappreciated complication of DM1 and is not addressed in most diabetes guidelines. There is also a lack of data regarding the efficacy of therapeutic strategies to treat osteoporosis in this patient population. Together, our current understanding of bone fragility in DM1 calls for an update of diabetes guidelines, better screening tools, and further research into the use of therapeutic strategies in this patient population. ","PeriodicalId":45384,"journal":{"name":"Journal of Osteoporosis","volume":"2015 ","pages":"174186"},"PeriodicalIF":1.9,"publicationDate":"2015-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1155/2015/174186","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"33217528","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 74